Background: In this paper, we report about new insights regarding clinical course, long-term outcome, ethnic/genetic predisposition and cardio-circulatory status in the large stress-induced cardiomyopathy (SIC) cohort from Sweden. Methods and Results: We have included 115 consecutive SIC patients between January 2005 and January 2010 at Sahlgrenska University Hospital in Gothenburg. Hemodynamic status and sympathetic nerve activity were evaluated and compared with those of healthy controls. Mean age was 64, and 14% were males. Thirty-day and 3-year mortality was 6 and 10%, respectively. Eleven percent had ischemic heart disease, 3% developed thromboembolic complications, 6% had cardiac arrest and 14% developed cardiogenic shock. The great majority of SIC patients (93%) were ethnic Swedes. In three families, several close relatives developed SIC. Fourteen percent developed two or more episodes of SIC. Hemodynamic evaluation has shown subnormal systemic vascular resistance, 22% lower sympathetic activity and preserved cardiac output in SIC patients. Conclusions: SIC affects both men and women of different ages and is associated with significant short- and long-term mortality. There is a strong signal for the presence of ethnic/genetic predisposition to develop SIC. Sympathetic activity and systemic vascular resistance are lower in SIC patients, suggesting that SIC is a cardio-circulatory phenomenon.

Keywords:
Takotsubo, Sympathetic nervous system, Acute heart failure, Acute coronary syndrome, Stress-induced cardiomyopathy
1.
Akashi YJ, Goldstein DS, Barbaro G, Ueyama T: Takotsubo cardiomyopathy: a new form of acute, reversible heart failure. Circulation 2008;118:2754–2762.
2.
Wittstein IS: Acute stress cardiomyopathy. Curr Heart Fail Rep 2008;5:61–68.
3.
Dote K, Sato H, Tateishi H, Uchida T, Ishihara M: Myocardial stunning due to simultaneous multivessel coronary spasms: a review of 5 cases (in Japanese). J Cardiol 1991;21:203–214.
4.
Ellison GM, Torella D, Karakikes I, Purushothaman S, Curcio A, Gasparri C, Indolfi C, Cable NT, Goldspink DF, Nadal-Ginard B: Acute beta-adrenergic overload produces myocyte damage through calcium leakage from the ryanodine receptor 2 but spares cardiac stem cells. J Biol Chem 2007;282:11397–11409.
5.
Ueyama T, Ishikura F, Matsuda A, Asanuma T, Ueda K, Ichinose M, Kasamatsu K, Hano T, Akasaka T, Tsuruo Y, Morimoto K, Beppu S: Chronic estrogen supplementation following ovariectomy improves the emotional stress-induced cardiovascular responses by indirect action on the nervous system and by direct action on the heart. Circ J 2007;71:565–573.
6.
Ueyama T, Kasamatsu K, Hano T, Tsuruo Y, Ishikura F: Catecholamines and estrogen are involved in the pathogenesis of emotional stress-induced acute heart attack. Ann NY Acad Sci 2008;1148:479–485.
7.
Abraham J, Mudd JO, Kapur NK, Klein K, Champion HC, Wittstein IS: Stress cardiomyopathy after intravenous administration of catecholamines and beta-receptor agonists. J Am Coll Cardiol 2009;53:1320–1325.
8.
Lagerqvist B, James SK, Stenestrand U, Lindback J, Nilsson T, Wallentin L: Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 2007;356:1009–1019.
9.
Stenestrand U, Lindback J, Wallentin L: Long-term outcome of primary percutaneous coronary intervention versus prehospital and in-hospital thrombolysis for patients with ST-elevation myocardial infarction. JAMA 2006;296:1749–1756.
10.
Omerovic E: How to think about stress-induced cardiomyopathy? – think ‘out of the box’! Scand Cardiovasc J 2011;45:67–71.
11.
Vallbo AB, Hagbarth KE, Torebjork HE, Wallin BG: Somatosensory, proprioceptive, and sympathetic activity in human peripheral nerves. Physiol Rev 1979;59:919–957.
12.
Sverrisdottir YB, Elam M, Caidahl K, Soderling AS, Herlitz H, Johannsson G: The effect of growth hormone (GH) replacement therapy on sympathetic nerve hyperactivity in hypopituitary adults: a double-blind, placebo-controlled, crossover, short-term trial followed by long-term open GH replacement in hypopituitary adults. J Hypertens 2003;21:1905–1914.
13.
Albert NM, Hail MD, Li J, Young JB: Equivalence of the bioimpedance and thermodilution methods in measuring cardiac output in hospitalized patients with advanced, decompensated chronic heart failure. Am J Crit Care 2004;13:469–479.
14.
Statistics Sweden. http://www.Scb.Se/.
15.
Hedemalm A, Schaufelberger M, Ekman I: Equality in the care and treatment of immigrants and native Swedes – a comparative study of patients hospitalised for heart failure. Eur J Cardiovasc Nurs 2008;7:222–228.
16.
Prasad A, Lerman A, Rihal CS: Apical ballooning syndrome (tako-tsubo or stress cardiomyopathy): a mimic of acute myocardial infarction. Am Heart J 2008;155:408–417.
17.
Wittstein IS, Thiemann DR, Lima JA, Baughman KL, Schulman SP, Gerstenblith G, Wu KC, Rade JJ, Bivalacqua TJ, Champion HC: Neurohumoral features of myocardial stunning due to sudden emotional stress. N Engl J Med 2005;352:539–548.
18.
Gaibazzi N, Ugo F, Vignali L, Zoni A, Reverberi C, Gherli T: Tako-tsubo cardiomyopathy with coronary artery stenosis: a case-series challenging the original definition. Int J Cardiol 2009;133:205–212.
19.
Kurisu S, Inoue I, Kawagoe T, Ishihara M, Shimatani Y, Nakama Y, Maruhashi T, Kagawa E, Dai K, Matsushita J, Ikenaga H: Prevalence of incidental coronary artery disease in tako-tsubo cardiomyopathy. Coron Artery Dis 2009;20:214–218.
20.
Winchester DE, Ragosta M, Taylor AM: Concurrence of angiographic coronary artery disease in patients with apical ballooning syndrome (tako-tsubo cardiomyopathy). Catheter Cardiovasc Interv 2008;72:612–616.
21.
Eitel I, von Knobelsdorff-Brenkenhoff F, Bernhardt P, Carbone I, Muellerleile K, Aldrovandi A, Francone M, Desch S, Gutberlet M, Strohm O, Schuler G, Schulz-Menger J, Thiele H, Friedrich MG: Clinical characteristics and cardiovascular magnetic resonance findings in stress (takotsubo) cardiomyopathy. JAMA 2011;306:277–286.
22.
Peterson ED, Roe MT, Mulgund J, DeLong ER, Lytle BL, Brindis RG, Smith SC Jr, Pollack CV Jr, Newby LK, Harrington RA, Gibler WB, Ohman EM: Association between hospital process performance and outcomes among patients with acute coronary syndromes. JAMA 2006;295:1912–1920.
23.
Koek HL, de Bruin A, Gast F, Gevers E, Kardaun JW, Reitsma JB, Grobbee DE, Bots ML: Short- and long-term prognosis after acute myocardial infarction in men versus women. Am J Cardiol 2006;98:993–999.
24.
Koek HL, Soedamah-Muthu SS, Kardaun JW, Gevers E, de Bruin A, Reitsma JB, Bots ML, Grobbee DE: Short- and long-term mortality after acute myocardial infarction: Comparison of patients with and without diabetes mellitus. Eur J Epidemiol 2007;22:883–888.
25.
Parodi G, Bellandi B, Del Pace S, Barchielli A, Zampini L, Velluzzi S, Carrabba N, Gensini GF, Antoniucci D: Natural history of tako-tsubo cardiomyopathy. Chest 2011;139:887–892.
26.
Sharkey SW, Windenburg DC, Lesser JR, Maron MS, Hauser RG, Lesser JN, Haas TS, Hodges JS, Maron BJ: Natural history and expansive clinical profile of stress (tako-tsubo) cardiomyopathy. J Am Coll Cardiol 2010;55:333–341.
27.
Page DL, Caulfield JB, Kastor JA, DeSanctis RW, Sanders CA: Myocardial changes associated with cardiogenic shock. N Engl J Med 1971;285:133–137.
28.
Sobel BE, Bresnahan GF, Shell WE, Yoder RD: Estimation of infarct size in man and its relation to prognosis. Circulation 1972;46:640–648.
29.
Akashi YJ, Musha H, Kida K, Itoh K, Inoue K, Kawasaki K, Hashimoto N, Miyake F: Reversible ventricular dysfunction takotsubo cardiomyopathy. Eur J Heart Fail 2005;7:1171–1176.
30.
Jepsen P, Johnsen SP, Gillman MW, Sorensen HAT: Interpretation of observational studies. Heart 2004;90:956–960.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.